Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

To compare serum 25-hydroxyvitamin D [25(OH)D] levels between patients with medication-related osteonecrosis of the jaw (MRONJ) and antiresorptive-exposed controls.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis

Source: Article title.

Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis

Systematic review · BMC Oral Health · 2026

Original publication title

Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis

Alireza Daneshvar; Kimia Daneshvar; Farhan Musaie; Sobhan Dashti; Niloofar Talebi Yazdi; Reza Tabrizi

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Postdiagnosis serum 25(OH)D levels appear similar in MRONJ patients and antiresorptive-exposed controls; however, the evidence is limited and of very low certainty, so conclusions should be interpreted cautiously.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To compare serum 25-hydroxyvitamin D [25(OH)D] levels between patients with medication-related osteonecrosis of the jaw (MRONJ) and antiresorptive-exposed controls.

Source: Objectives

Abstract: What methods does the paper describe?

Following PRISMA guidelines, PubMed, Scopus, Web of Science, and Embase were searched through September 2025 for studies including adults (≥ 18 years) treated with bisphosphonates or denosumab that reported 25(OH)D levels in MRONJ cases and exposed controls. Random-effects models generated standardized mean differences (SMDs) with 95% confidence intervals (CIs). Heterogeneity, influence and subgroup analyses, random-effects meta-regression, and publication bias (Egger’s and Begg’s tests) were assessed.

Source: Materials and methods

Abstract: Clinical relevance

In antiresorptive-treated adults, serum 25-hydroxyvitamin D levels measured after diagnosis do not differ meaningfully between patients with MRONJ and exposed controls, suggesting vitamin D is unlikely to be a primary determinant of MRONJ occurrence but may still modify disease course.

Source: Clinical relevance

Abstract: Results

Six studies (five case: control, one cohort; 184 MRONJ, 175 controls) met inclusion criteria. Mean serum 25(OH)D was 33.16 ± 4.27 ng/mL in MRONJ patients and 36.86 ± 5.02 ng/mL in controls. The SMD was − 0.06 (95% CI, − 0.51 to 0.39; p = 0.79) with heterogeneity (I² = 75.0%; p < 0.001). After exclusion of two influential studies, heterogeneity decreased to 0% and the SMD remained non-significant (− 0.11; 95% CI, − 0.36 to 0.15; p = 0.41). Subgroup analyses by indication/population (mixed osteoporosis plus oncologic versus exclusively oncologic) showed no significant differences.

Meta-regression indicated that control sample size and bisphosphonate exposure duration in MRONJ groups were associated with effect size. The certainty of evidence for the analyzed outcome was very low.

Source: Results

Abstract: Conclusions

Postdiagnosis serum 25(OH)D levels appear similar in MRONJ patients and antiresorptive-exposed controls; however, the evidence is limited and of very low certainty, so conclusions should be interpreted cautiously.

Source: Conclusions
Authors’ abstract

Objectives

To compare serum 25-hydroxyvitamin D [25(OH)D] levels between patients with medication-related osteonecrosis of the jaw (MRONJ) and antiresorptive-exposed controls.

Materials and methods

Following PRISMA guidelines, PubMed, Scopus, Web of Science, and Embase were searched through September 2025 for studies including adults (≥ 18 years) treated with bisphosphonates or denosumab that reported 25(OH)D levels in MRONJ cases and exposed controls. Random-effects models generated standardized mean differences (SMDs) with 95% confidence intervals (CIs). Heterogeneity, influence and subgroup analyses, random-effects meta-regression, and publication bias (Egger’s and Begg’s tests) were assessed.

Results

Six studies (five case: control, one cohort; 184 MRONJ, 175 controls) met inclusion criteria. Mean serum 25(OH)D was 33.16 ± 4.27 ng/mL in MRONJ patients and 36.86 ± 5.02 ng/mL in controls. The SMD was − 0.06 (95% CI, − 0.51 to 0.39; p = 0.79) with heterogeneity (I² = 75.0%; p < 0.001). After exclusion of two influential studies, heterogeneity decreased to 0% and the SMD remained non-significant (− 0.11; 95% CI, − 0.36 to 0.15; p = 0.41). Subgroup analyses by indication/population (mixed osteoporosis plus oncologic versus exclusively oncologic) showed no significant differences.

Meta-regression indicated that control sample size and bisphosphonate exposure duration in MRONJ groups were associated with effect size. The certainty of evidence for the analyzed outcome was very low.

Conclusions

Postdiagnosis serum 25(OH)D levels appear similar in MRONJ patients and antiresorptive-exposed controls; however, the evidence is limited and of very low certainty, so conclusions should be interpreted cautiously.

Clinical relevance

In antiresorptive-treated adults, serum 25-hydroxyvitamin D levels measured after diagnosis do not differ meaningfully between patients with MRONJ and exposed controls, suggesting vitamin D is unlikely to be a primary determinant of MRONJ occurrence but may still modify disease course.

Trial registration

CRD420251172147.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12903-026-08303-9.

Publication and source details

Original title: Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis

Alireza Daneshvar; Kimia Daneshvar; Farhan Musaie; Sobhan Dashti; Niloofar Talebi Yazdi; Reza Tabrizi

BMC Oral Health · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T16:26:12.380182+00:00

DOI: 10.1186/s12903-026-08303-9 · PMC13270808